Recent Posts
- Illinois Attorney General Files Lawsuit Against HIV/AIDS Nonprofit
- California Gov. Arnold Schwarzenegger Signs Budget That Cuts $52M From HIV/AIDS Programs
- Efforts Underway In Namibia To Treat Pediatric HIV
- HIV/AIDS Education Project Targeting Pennsylvania Black Women Examined
- Also In Global Health News: Uganda Male Circumcision; Malaria Vaccine; Potential Global Fund Grant In Cambodia; PMTCT Of HIV In Botswana
Random Posts
- New Survey Targets Over 50s Living With HIV, UK
- Los Angeles County Health Officials Retract Report About HIV Cases In Adult Film Industry
- California's AIDS Funding Cuts Would Be 'Catastrophic,' Says AHF
- Clinton Heads To Kenya As Africa Visit Begins
- Continued International Investment, Decreased Discrimination Key To Fight Against HIV/AIDS, Says U.N. Secretary-General
- IAS Conference: Low-Cost CD4 Tests; HIV Prevalence Among Pregnant Zimbabweans; Treating HIV-TB With ARVs; Vaccine Trials
- GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
- 10th Functional Genomics: Chemical Biology 2009
- Terrence Higgins Trust Runners Get 'hot And Sweaty' To Raise Awareness Of HIV In Bristol Half Marathon
- Leading Vaccine Discovery Expert Joins The International AIDS Vaccine Initiative (IAVI)
Prescription AIDS Drugs
Contact Us
Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment
August 06th, 2009
| Patient / Public: |  |
5 (1 votes) |
| Health Professional: |  |
|
| Article Opinions: | 0 posts |
Foster City, Calif.-based Gilead Sciences on Thursday said it has entered into a license and collaboration agreement with Johnson and Johnson subsidiary Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose treatment for HIV, the San Francisco Business Times reports. The FDA approved the first once-daily HIV treatment Atripla in 2006 (7/16). The new antiretroviral drug would contain Tibotec’s experimental non-nucleoside reverse transcriptase inhibitor, known as TMC278, and Gilead’s combination pill, Truvada. Kevin Young, head of commercial operations at Gilead “said the new combination pill, along with Gilead’s experimental ‘quad’ pill, will be used for newly-diagnosed patients, with physicians reluctant to change therapy for patients who are responding well to Atripla,” Reuters reports. Young said the drug is expected to reach the market in 2011 (Beasley, 7/16).
This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org.
© Henry J. Kaiser Family Foundation. All rights reserved.
Related posts:
- Raltegravir Combination Treatment For HIV Is A Safe And Effective Alternative To Efavirenz In Treatment-Naive Patients Use of the HIV antiretroviral treatment raltegravir, in combination with...
- Einstein To Develop Anti-HIV Drug Delivery System The National Institutes of Health has awarded Albert Einstein College...
- Focusing On The HIV Virus: £1.7M Award To Develop Nanotechnology For Use In Health Care Scientists at the University of Liverpool have been awarded £1.7...
- Schering-Plough Expands Vicriviroc Phase II Study In Treatment-Naive Patients With HIV Schering-Plough Corporation (NYSE: SGP) announced that it has extended to...
- Viriom Selects ChemDiv To Develop HIV Program ChemDiv, Inc. (ChemDiv) of San Diego has proudly announced that...
Related posts brought to you by Yet Another Related Posts Plugin.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.